Glenmark gets license to market Akynzeo in India

4 April 2018

Privately-held Swiss drugmaker Helsinn has entered into a licensing agreement with Indian drugmaker Glenmark Pharmaceuticals (BSE: 532296) to introduce Akynzeo, an oral fixed combination of netupitant and palonosetron, in India and Nepal.

Akynzeo is used for prevention of chemotherapy-induced nausea and vomiting (CINV). The licensing deal with Glenmark for Akynzeo represents Helsinn’s first such agreement in India. No financial terms of the accord have been released

Glenmark, which has already received marketing approval for Akynzeo from India’s Central Drugs Standard Control Organization (CDSCO), will have exclusive marketing rights for the drug in India and Nepal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK